These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

418 related items for PubMed ID: 17785900

  • 1. Current status of iron overload and chelation with deferasirox.
    Choudhry VP, Naithani R.
    Indian J Pediatr; 2007 Aug; 74(8):759-64. PubMed ID: 17785900
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Deferasirox for managing iron overload in people with thalassaemia.
    Meerpohl JJ, Antes G, Rücker G, Fleeman N, Motschall E, Niemeyer CM, Bassler D.
    Cochrane Database Syst Rev; 2012 Feb 15; (2):CD007476. PubMed ID: 22336831
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pharmacoeconomic benefits of deferasirox in the management of iron overload syndromes.
    Imran F, Phatak P.
    Expert Rev Pharmacoecon Outcomes Res; 2009 Aug 15; 9(4):297-304. PubMed ID: 19670988
    [Abstract] [Full Text] [Related]

  • 9. Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.
    Fortin PM, Fisher SA, Madgwick KV, Trivella M, Hopewell S, Doree C, Estcourt LJ.
    Cochrane Database Syst Rev; 2018 May 08; 5(5):CD012349. PubMed ID: 29737522
    [Abstract] [Full Text] [Related]

  • 10. Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload.
    Cappellini MD, Taher A.
    Expert Opin Pharmacother; 2008 Sep 08; 9(13):2391-402. PubMed ID: 18710363
    [Abstract] [Full Text] [Related]

  • 11. A pharmaco-economic evaluation of deferasirox for treating patients with iron overload caused by transfusion-dependent thalassemia in Taiwan.
    Ho WL, Chung KP, Yang SS, Lu MY, Jou ST, Chang HH, Yang YL, Lin DT, Lin KH.
    J Formos Med Assoc; 2013 Apr 08; 112(4):221-9. PubMed ID: 23537869
    [Abstract] [Full Text] [Related]

  • 12. Deferasirox : a review of its use in the management of transfusional chronic iron overload.
    Yang LP, Keam SJ, Keating GM.
    Drugs; 2007 Apr 08; 67(15):2211-30. PubMed ID: 17927285
    [Abstract] [Full Text] [Related]

  • 13. Do we need more iron-chelating drugs?
    Kontoghiorghes GJ.
    Lancet; 2003 Aug 09; 362(9382):495-6. PubMed ID: 12927446
    [No Abstract] [Full Text] [Related]

  • 14. Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging.
    Pepe A, Meloni A, Capra M, Cianciulli P, Prossomariti L, Malaventura C, Putti MC, Lippi A, Romeo MA, Bisconte MG, Filosa A, Caruso V, Quarta A, Pitrolo L, Missere M, Midiri M, Rossi G, Positano V, Lombardi M, Maggio A.
    Haematologica; 2011 Jan 09; 96(1):41-7. PubMed ID: 20884710
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Cost-utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United Kingdom.
    Karnon J, Tolley K, Oyee J, Jewitt K, Ossa D, Akehurst R.
    Curr Med Res Opin; 2008 Jun 09; 24(6):1609-21. PubMed ID: 18439348
    [Abstract] [Full Text] [Related]

  • 17. [Iron chelating therapy in adults: How and when ?].
    Ruivard M.
    Rev Med Interne; 2013 Jan 09; 34(1):32-8. PubMed ID: 23195912
    [Abstract] [Full Text] [Related]

  • 18. Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation.
    McLeod C, Fleeman N, Kirkham J, Bagust A, Boland A, Chu P, Dickson R, Dundar Y, Greenhalgh J, Modell B, Olujohungbe A, Telfer P, Walley T.
    Health Technol Assess; 2009 Jan 09; 13(1):iii-iv, ix-xi, 1-121. PubMed ID: 19068191
    [Abstract] [Full Text] [Related]

  • 19. Cost-utility analysis of oral deferasirox versus infusional deferoxamine in transfusion-dependent β-thalassemia patients.
    Keshtkaran A, Javanbakht M, Salavati S, Mashayekhi A, Karimi M, Nuri B.
    Transfusion; 2013 Aug 09; 53(8):1722-9. PubMed ID: 23241074
    [Abstract] [Full Text] [Related]

  • 20. Chelation therapy for iron overload.
    Barton JC.
    Curr Gastroenterol Rep; 2007 Mar 09; 9(1):74-82. PubMed ID: 17335681
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.